James P. Brady
Human Resources Officer at SPERO THERAPEUTICS, INC.
James P. Brady active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SPERO THERAPEUTICS, INC. | Human Resources Officer | - | - |
Career history of James P. Brady
Former positions of James P. Brady
| Companies | Position | Start | End |
|---|---|---|---|
| UNIQURE N.V. | Human Resources Officer | 01/08/2020 | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Human Resources Officer | 01/04/2015 | - |
Training of James P. Brady
| Marietta College | Undergraduate Degree |
| Harvard University | Graduate Degree |
Statistics
International
| United States | 5 |
| Netherlands | 2 |
Operational
| Human Resources Officer | 3 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| UNIQURE N.V. | Health Technology |
| SPERO THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- James P. Brady
- Experience
